ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc (ZNTL)

2.965
-0.095
( -3.10% )
Actualizado: 09:37:50

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
2.965
Postura de Compra
2.96
Postura de Venta
2.97
Volume Operado de la Acción
113,380
2.93 Rango del Día 3.07
2.6612 Rango de 52 semanas 18.07
Capitalización de Mercado [m]
Precio Anterior
3.06
Precio de Apertura
3.00
Última hora de negociación
09:38:42
Volumen financiero
US$ 338,009
Precio Promedio Ponderado
2.9812
Volumen promedio (3 m)
1,233,152
Acciones en circulación
71,265,400
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.72
Beneficio por acción (BPA)
-4.1
turnover
-
Beneficio neto
-292.19M

Acerca de Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Zentalis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZNTL. The last closing price for Zentalis Pharmaceuticals was US$3.06. Over the last year, Zentalis Pharmaceuticals shares have traded in a share price range of US$ 2.6612 to US$ 18.07.

Zentalis Pharmaceuticals currently has 71,265,400 shares in issue. The market capitalisation of Zentalis Pharmaceuticals is US$218.07 million. Zentalis Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.72.

ZNTL Últimas noticias

Zentalis Pharmaceuticals Announces Key Management Appointments

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...

Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.165-5.271565495213.133.322.937073083.15548362CS
4-0.745-20.08086253373.7142.79510596563.25247921CS
12-0.265-8.204334365333.234.442.661212331523.27754021CS
26-1.125-27.50611246944.095.442.661214687863.55255894CS
52-11.915-80.073924731214.8818.072.661212689136.29042255CS
156-80.375-96.442284617283.3485.952.661289377815.79104699CS
260-21.725-87.991089509924.6987.192.661265967621.07926201CS

ZNTL - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Zentalis Pharmaceuticals?
El precio actual de las acciones de Zentalis Pharmaceuticals es US$ 2.965
¿Cuántas acciones de Zentalis Pharmaceuticals están en circulación?
Zentalis Pharmaceuticals tiene 71,265,400 acciones en circulación
¿Cuál es la capitalización de mercado de Zentalis Pharmaceuticals?
La capitalización de mercado de Zentalis Pharmaceuticals es USD 218.07M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals ha negociado en un rango de US$ 2.6612 a US$ 18.07 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Zentalis Pharmaceuticals?
El ratio precio/beneficio de Zentalis Pharmaceuticals es -0.72
¿Cuál es la moneda de reporte de Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Zentalis Pharmaceuticals?
El último beneficio anual de Zentalis Pharmaceuticals es USD -292.19M
¿Cuál es la dirección registrada de Zentalis Pharmaceuticals?
La dirección registrada de Zentalis Pharmaceuticals es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Zentalis Pharmaceuticals?
La dirección del sitio web de Zentalis Pharmaceuticals es www.zentalis.com
¿En qué sector industrial opera Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WATTEnergous Corporation
US$ 1.9394
(371.64%)
124.85M
NXUNXU Inc
US$ 0.82
(236.89%)
220.09M
INTZIntrusion Inc
US$ 5.81
(168.98%)
93.42M
VINCVincerx Inc
US$ 0.4223
(117.68%)
228.4M
HOLOMicroCloud Hologram Inc
US$ 4.01
(67.08%)
68.86M
ABPAbpro Holdings Inc
US$ 2.35
(-47.66%)
618.56k
TRAWTraws Pharma Inc
US$ 8.21
(-38.82%)
751.44k
LITMSnow Lake Resources Ltd
US$ 1.185
(-25.94%)
35.01M
BITSGlobal X Blockchain and Bitcoin Stratagy ETF
US$ 66.00
(-25.39%)
5.71k
LICNLichen China Limited
US$ 0.1799
(-22.49%)
22.78M
VINCVincerx Inc
US$ 0.42405
(118.58%)
228.6M
NXUNXU Inc
US$ 0.84
(245.11%)
220.29M
WATTEnergous Corporation
US$ 1.99
(383.95%)
125.29M
XTIAXTI Aerospace Inc
US$ 0.0399
(1.01%)
123.05M
INTZIntrusion Inc
US$ 5.755
(166.44%)
93.43M

ZNTL Discussion

Ver más
Awl416 Awl416 3 meses hace
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
👍️0
glenn1919 glenn1919 3 meses hace
ZNTL.......................................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 meses hace
ZNTL under $4
👍️0
ANTADOG ANTADOG 4 años hace
We managed to get a new 26 week high and a reset around 46 bucks, will be interesting to see where it goes next, chartwise it's up, imo of course, ANT
👍️0
ANTADOG ANTADOG 5 años hace
Added some 46's , nice chart reset, ANT
👍️0
ANTADOG ANTADOG 5 años hace
55.12~~ looks like this puppy is on it's way for a new 52 week high, my target here is 100 bucks because of the very promising pipeline , fyi imo ANT
👍️0
ANTADOG ANTADOG 5 años hace
NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. ZN-c5 also displayed excellent oral bioavailability across several preclinical species. ZN-c5 is currently being evaluated in a Phase 1/2 clinical trial in patients with ER+/HER2- advanced or metastatic breast cancer both as a single agent and in combination studies.
👍️0
ANTADOG ANTADOG 5 años hace
NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
fyi ANT
👍️0
ANTADOG ANTADOG 5 años hace
New 52 week high at 52.09, i luv it, ANT
👍️0
ANTADOG ANTADOG 5 años hace
Cash Position: As of March 31, 2020, Zentalis had cash and cash equivalents of $63.7 million. We expect that the Company’s existing cash and cash equivalents, together with the net proceeds of $172.4 million from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
fyi ANT
👍️0
ANTADOG ANTADOG 5 años hace
Chart is pretty fresh here, anyway, i see a trendline curlin' up already (10ma on the daily at 35.9), fyi ANT
👍️0
ANTADOG ANTADOG 5 años hace
promisin' co, interestin' pipeline, touched new 52 week high today (42.83), enormous spread every now and then, fyi ANT
👍️0
crudeoil24 crudeoil24 5 años hace
ZNTL opens @ 25.20 >
👍️0
crudeoil24 crudeoil24 5 años hace
Zentalis Pharma Upsized IPO Prices at High End of Range >ZNTL
6:08 am ET April 3, 2020 (Dow Jones) Print
By Colin Kellaher

Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.

The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.

Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.

Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2020 06:08 ET (10:08 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
👍️0
crudeoil24 crudeoil24 5 años hace
Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
👍️0

Su Consulta Reciente